PureTech Health Says LYT-200 Shows 'Robust' Antileukemic Activity in Phase 1b Trial

MT Newswires Live04-22

PureTech Health (PRTC) said Wednesday that topline results from a phase 1b trial evaluating LYT-200 in heavily pretreated patients with relapsed/refractory high-risk myelodysplastic syndrome and relapsed/refractory acute myeloid leukemia showed "robust" antileukemic activity and a "favorable" safety profile.

The company said that LYT-200 combined with a hypomethylating agent delivered complete responses, bridging to transplant, and durable clinical benefit.

LYT-200 also demonstrated a consistent safety profile across all cohorts and dose levels studied, the company said.

The company said its Gallop Oncology unit has selected a recommended dose for a phase 2 study in relapsed/refractory high-risk myelodysplastic syndrome and plans to engage with the US Food and Drug Administration to discuss trial design.

Price: 18.04, Change: +0.04, Percent Change: +0.22

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2629047494?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-22 22:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2629047494","market":"nz","top_or_hot":-1,"title":"PureTech Health Says LYT-200 Shows 'Robust' Antileukemic Activity in Phase 1b Trial","media":"MT Newswires Live","content":"<html><body><p> PureTech Health (PRTC) said Wednesday that topline results from a phase 1b trial evaluating LYT-200 in heavily pretreated patients with relapsed/refractory high-risk myelodysplastic syndrome and relapsed/refractory acute myeloid leukemia showed \"robust\" antileukemic activity and a \"favorable\" safety profile.</p><p>The company said that LYT-200 combined with a hypomethylating agent delivered complete responses, bridging to transplant, and durable clinical benefit.</p><p>LYT-200 also demonstrated a consistent safety profile across all cohorts and dose levels studied, the company said.</p><p>The company said its Gallop Oncology unit has selected a recommended dose for a phase 2 study in relapsed/refractory high-risk myelodysplastic syndrome and plans to engage with the US Food and Drug Administration to discuss trial design.</p><p>Price: 18.04, Change: +0.04, Percent Change: +0.22</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PureTech Health Says LYT-200 Shows 'Robust' Antileukemic Activity in Phase 1b Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPureTech Health Says LYT-200 Shows 'Robust' Antileukemic Activity in Phase 1b Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-04-22 22:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> PureTech Health (PRTC) said Wednesday that topline results from a phase 1b trial evaluating LYT-200 in heavily pretreated patients with relapsed/refractory high-risk myelodysplastic syndrome and relapsed/refractory acute myeloid leukemia showed \"robust\" antileukemic activity and a \"favorable\" safety profile.</p><p>The company said that LYT-200 combined with a hypomethylating agent delivered complete responses, bridging to transplant, and durable clinical benefit.</p><p>LYT-200 also demonstrated a consistent safety profile across all cohorts and dose levels studied, the company said.</p><p>The company said its Gallop Oncology unit has selected a recommended dose for a phase 2 study in relapsed/refractory high-risk myelodysplastic syndrome and plans to engage with the US Food and Drug Administration to discuss trial design.</p><p>Price: 18.04, Change: +0.04, Percent Change: +0.22</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4108","symbol_name":"电影和娱乐","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2629047494","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2629047494","pubTimestamp":1776866755,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"PureTech Health (PRTC) said Wednesday that topline results from a phase 1b trial evaluating LYT-200 in heavily pretreated patients with relapsed/refractory high-risk myelodysplastic syndrome and relap","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4108":"电影和娱乐","BK4139":"生物科技","LYT":"Lytus Technologies Holdings","PRTC":"PureTech Health PLC"},"translate_title":"PureTech Health表示LYT-200在1b期试验中显示出“强大”的抗白血病活性","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRTC":1,"LYT":1.5},"content_text":"PureTech Health (PRTC) said Wednesday that topline results from a phase 1b trial evaluating LYT-200 in heavily pretreated patients with relapsed/refractory high-risk myelodysplastic syndrome and relapsed/refractory acute myeloid leukemia showed \"robust\" antileukemic activity and a \"favorable\" safety profile.The company said that LYT-200 combined with a hypomethylating agent delivered complete responses, bridging to transplant, and durable clinical benefit.LYT-200 also demonstrated a consistent safety profile across all cohorts and dose levels studied, the company said.The company said its Gallop Oncology unit has selected a recommended dose for a phase 2 study in relapsed/refractory high-risk myelodysplastic syndrome and plans to engage with the US Food and Drug Administration to discuss trial design.Price: 18.04, Change: +0.04, Percent Change: +0.22","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2629047494","isCrawlerRequest":true}